Get the Stockscreener App
6.25
0.64%
0.04
After Hours:
6.10
-0.15
-2.40%
Journey Medical Corp stock is traded at $6.25, with a volume of 53,673.
It is up +0.64% in the last 24 hours and up +17.70% over the past month.
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
See More
Previous Close:
$6.21
Open:
$6.14
24h Volume:
53,673
Relative Volume:
0.80
Market Cap:
$143.48M
Revenue:
$56.13M
Net Income/Loss:
$-14.67M
P/E Ratio:
-8.4459
EPS:
-0.74
Net Cash Flow:
$-9.13M
1W Performance:
+3.14%
1M Performance:
+17.70%
6M Performance:
+4.69%
1Y Performance:
+61.92%
1-Day Range:
$6.05
$6.30
1-Week Range:
$5.7244
$6.40
52-Week Range:
$3.2001
$7.29
Journey Medical Corp Stock (DERM) Company Profile
Name
Journey Medical Corp
Sector
Phone
480-434-6670
Address
9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE
Compare DERM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DERM
Journey Medical Corp
|
6.25 | 143.48M | 56.13M | -14.67M | -9.13M | -0.74 |
|
ZTS
Zoetis Inc
|
148.67 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.22 | 45.62B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.71 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.65 | 15.60B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
284.73 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Journey Medical Corp Stock (DERM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-28-24 | Resumed | ROTH MKM | Buy |
| Dec-07-21 | Initiated | B. Riley Securities | Buy |
Journey Medical Corp Stock (DERM) Latest News
Is The Walt Disney Company (DIS) the Best Metaverse Stock to Invest in? - Yahoo Finance
Is Autodesk (ADSK) the Best Metaverse Stock to Invest in? - Yahoo Finance
Is Lumen Technologies (LUMN) the Most Promising Penny Stock According to Analysts? - Yahoo Finance
JPMorgan says Lilly data ‘highly favorable’ for Structure Therapeutics - Yahoo Finance
Are Journey Medical Corp (NASDAQ: DERM) Analysts Predicting A Spike? - stocksregister.com
10 Cheap Hot Stocks to Buy Right Now - Insider Monkey
McKesson Careers | The future of health starts with you. - McKesson Careers
FBIO stock touches 52-week low at $1.35 amid market challenges - Investing.com
Top 3 Health Care Stocks That May Crash In Q2 - Benzinga
Journey Medical (DERM) Surges 9.1%: Is This an Indication of Further Gains? - Yahoo Finance
Journey Medical stock soars to 52-week high of $6.93 - Investing.com Australia
Journey Medical stock soars to 52-week high of $6.93 By Investing.com - Investing.com Canada
Journey Medical Corp Appoints New Chief Operating Officer - TipRanks
Brokers Set Expectations for Journey Medical FY2027 Earnings - MarketBeat
Q1 EPS Estimates for Journey Medical Reduced by Roth Capital - MarketBeat
Journey Medical appoints new COO amid growth phase - Investing.com
Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer - The Globe and Mail
BME INNOVATION 2025: A JOURNEY MARKED BY INNOVATION - Trường Đại học Quốc Tế
Journey Medical Strengthens Leadership: New COO to Drive Emrosi Launch Strategy - Stock Titan
Journey Medical (NASDAQ:DERM) Issues Earnings Results - MarketBeat
Q3 EPS Estimates for Journey Medical Boosted by Roth Capital - MarketBeat
Roth Capital Lowers Earnings Estimates for Journey Medical - Defense World
FY2027 EPS Estimate for Journey Medical Decreased by Analyst - Defense World
Q3 EPS Estimates for Journey Medical Increased by Analyst - Defense World
Journey Medical Corporation (NASDAQ:DERM) Q4 2024 Earnings Call Transcript - Insider Monkey
Journey Medical Reports 2024 Financial Results - TipRanks
Journey Medical’s Earnings Call Highlights MROSI Launch and Growth Potential - TipRanks
Journey Medical Corp (DERM) Q4 2024 Earnings Call Highlights: Strategic Launch of Emrosi and ... By GuruFocus - Investing.com Canada
Journey Medical earnings beat by $0.27, revenue fell short of estimates - Investing.com
Earnings call transcript: Journey Medical Q4 2024 reveals revenue miss By Investing.com - Investing.com South Africa
Earnings call transcript: Journey Medical Q4 2024 reveals revenue miss - Investing.com
Earnings call transcript: Journey Medical’s Q4 2024 results highlight IMROCI launch - Investing.com
Journey Medical Corporation (DERM) Tops Q4 Earnings Estimates - Yahoo Finance
Journey Medical reports FY24 EPS (72c) vs (21c) last year - TipRanks
Journey Medical Corp reports results for the quarter ended December 31Earnings Summary - TradingView
FDA Green Light for Journey Medical's Rosacea Drug Reshapes 2024 Performance - Stock Titan
Earnings Scheduled For March 26, 2025 - Benzinga
New Study Compares Topical Serum and Pulse Light Therapy for Rosacea - Dermatology Times
Journey Medical launches Emrosi for the treatment of rosacea - Yahoo Finance
Power Up the Teyvat Journey: UGREEN Launches Genshin Impact Co-Branded Charging Collection - Yahoo Finance
23andMe's journey from DNA testing pioneer to bankruptcy - Yahoo Finance
Journey Medical Launches Emrosi, a Dual-Release Minocycline for Rosacea - Dermatology Times
Breakthrough: First Low-Dose Minocycline Treatment for Rosacea Shows Superior Results - Stock Titan
Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea - Yahoo Finance
Short Interest in Journey Medical Co. (NASDAQ:DERM) Grows By 20.5% - MarketBeat
Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025 - Yahoo Finance
AI Breakthrough: Fortress Biotech's New Partnership Transforms Drug Development Process - Stock Titan
Journey Medical (DERM) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Claude Maraoui Sells 49,271 Shares of Journey Medical Co. (NASDAQ:DERM) Stock - MarketBeat
Journey Medical Co. (NASDAQ:DERM) CEO Sells $74,674.05 in Stock - MarketBeat
Journey Medical Corp Stock (DERM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):